FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis

OBJECTIVE: Fibroblast growth factor 21 (FGF21) shows great potential for the treatment of obesity and type 2 diabetes, as its long-acting analogue reduces body weight and improves lipid profiles of participants in clinical studies; however, the intracellular mechanisms mediating these effects are po...

Descripción completa

Detalles Bibliográficos
Autores principales: Mottillo, Emilio P., Desjardins, Eric M., Fritzen, Andreas M., Zou, Vito Z., Crane, Justin D., Yabut, Julian M., Kiens, Bente, Erion, Derek M., Lanba, Adhiraj, Granneman, James G., Talukdar, Saswata, Steinberg, Gregory R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444097/
https://www.ncbi.nlm.nih.gov/pubmed/28580278
http://dx.doi.org/10.1016/j.molmet.2017.04.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444097/
https://www.ncbi.nlm.nih.gov/pubmed/28580278
http://dx.doi.org/10.1016/j.molmet.2017.04.001

Ejemplares similares